Inhaled Ibuprofen to Treat COVID-19 (CórdobaTrail)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04382768|
Recruitment Status : Recruiting
First Posted : May 11, 2020
Last Update Posted : June 11, 2020
Química Luar SRL
National Council of Scientific and Technical Research, Argentina
Centro de Excelencia en Productos y Procesos Córdoba
Information provided by (Responsible Party):
Néstor H García, National Council of Scientific and Technical Research, Argentina
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Recruiting|
|Estimated Primary Completion Date :||January 2021|
|Estimated Study Completion Date :||January 2021|
Publications of Results:
Muñoz AJ, Alasino RV, Garro AG, Heredia V, García NH, Cremonezzi DC, Beltramo DM. High Concentrations of Sodium Chloride Improve Microbicidal Activity of Ibuprofen against Common Cystic Fibrosis Pathogens. Pharmaceuticals (Basel). 2018 May 17;11(2). pii: E47. doi: 10.3390/ph11020047.
He L, Ding Y, Zhang Q, Che X, He Y, Shen H, Wang H, Li Z, Zhao L, Geng J, Deng Y, Yang L, Li J, Cai J, Qiu L, Wen K, Xu X, Jiang S. Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS. J Pathol. 2006 Nov;210(3):288-97.
Veljkovic V, Vergara-Alert J, Segalés J, Paessler S. Use of the informational spectrum methodology for rapid biological analysis of the novel coronavirus 2019-nCoV: prediction of potential receptor, natural reservoir, tropism and therapeutic/vaccine target. Version 4. F1000Res. 2020 Jan 27 [revised 2021 Jan 1];9:52. doi: 10.12688/f1000research.22149.4. eCollection 2020.